Table of Contents
Experimental Evidence
Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a gain of function (GOF).1
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| 1 | High-confidence DLBCL gene | |
| 2 | Role of MYD88 mutations in FL requires confirmation | |
| 1 | High-confidence MZL gene |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
DLBCL
Failed to render page: conflicting chdir during another chdir block
FL
Failed to render page: conflicting chdir during another chdir block
Mutation pattern and selective pressure estimates
Failed to render page: conflicting chdir during another chdir block
MYD88 Hotspots
| Chromosome | Coordinate (hg19) | ref>alt | HGVSp |
|---|---|---|---|
| chr3 | 38182641 | T>C | L265P |
Failed to render page: conflicting chdir during another chdir block
Expression
Failed to render page: conflicting chdir during another chdir block
References
1.
Ngo
VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W,
Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A,
Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E,
Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook
JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active
MYD88 mutations in human lymphoma. Nature. 2011 Feb
3;470(7332):115–119. PMCID: PMC5024568
2.
Yan
Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N, Hamoudi RA, Isaacson PG,
de Leval L, Wotherspoon A, Du MQ. BCR and TLR
signaling pathways are recurrently targeted by genetic changes in
splenic marginal zone lymphomas. Haematologica. 2012 Apr;97(4):595–598.
PMCID: PMC3347666